Concurrent Investment Advisors LLC Increases Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Concurrent Investment Advisors LLC boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 29.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,066 shares of the company’s stock after purchasing an additional 4,069 shares during the period. Concurrent Investment Advisors LLC’s holdings in Hims & Hers Health were worth $365,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after buying an additional 136,907 shares during the last quarter. Forerunner Ventures Management LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter worth approximately $86,836,000. Dimensional Fund Advisors LP grew its position in shares of Hims & Hers Health by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after buying an additional 193,507 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Hims & Hers Health by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after buying an additional 22,009 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HIMS. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. TD Cowen lifted their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Bank of America lifted their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Finally, Citigroup lowered Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Hims & Hers Health Trading Down 1.7 %

Hims & Hers Health stock opened at $14.49 on Wednesday. The business’s fifty day simple moving average is $18.74 and its two-hundred day simple moving average is $16.77. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of -1,448.50 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same period in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the transaction, the director now owns 23,917 shares in the company, valued at $362,342.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the transaction, the director now owns 23,917 shares in the company, valued at $362,342.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the transaction, the insider now owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The disclosure for this sale can be found here. Insiders sold 637,336 shares of company stock worth $12,543,913 over the last quarter. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.